FindTrial
Sign In

Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis

Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00265252
Enrollment
60
Registered
2005-12-14
Start date
2005-06-30
Completion date
2008-06-30
Last updated
2008-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Traumatic Osteonecrosis

Keywords

osteonecrosis, total hip replacement

Brief summary

To determine the cumulative incidence of total hip replacement, time to event after treatment with Fosamax or placebo during the study peroid

Detailed description

To determine the cumulative incidence of total hip replacement and collpase of femoral head, time to event after treatment with Fosamax or placebo during the study peroid

Interventions

DRUGAlendronate

Sponsors

Merck Sharp & Dohme LLC
CollaboratorINDUSTRY
National Cheng-Kung University Hospital
CollaboratorOTHER
National Taiwan University Hospital
CollaboratorOTHER
Kaohsiung Medical University Chung-Ho Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* osteonecrosis of femoral head * be able to provide singed informed consent

Exclusion criteria

* prior bisphosphonate use * pregnant or lactating woman * bilateral hip replacement

Design outcomes

Primary

MeasureTime frame
the cumulative of total hip replacement—

Secondary

MeasureTime frame
necrotic area—
Harris hip score—

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026